Clinical Trial

A Phase 1 Study of Cizutamig in IgE Mediated Diseases

Withdrawn Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-07-23
critical Reason stopped changed: — → Sponsor decision 2026-07-23
notable Enrollment reduced: 20 -> 0 participants 2026-07-23
Trial Details
NCT Number NCT07408869
Lead Sponsor Candid Therapeutics
Conditions IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy, IgE-Mediated Cow Milk Allergy
Start Date 2026-04
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-22